ArticleFrontiers in immunology2025
Multiomics analysis demonstrated that TOPBP1 interacting checkpoint and Replication Regulator may serve as an immune-related biomarker indicative of poor prognosis in lung adenocarcinoma.
Article in Frontiers in immunology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Lung adenocarcinoma (LUAD) persists as a leading contributor to global cancer-associated mortality. Identifying key oncogenic drivers is crucial for improving therapeutic strategies. This study aimed to investigate the role of TICRR in LUAD progression and its potential as a therapeutic target. Methods: Hub genes were screened through integration of DepMap CRISPR-Cas9 data, TCGA expression profiles, and survival analysis. TICRR expressions was assessed in LUAD tissues, adjacent controls, and cell lines by RT-qPCR and immunohistochemistry. Functional roles were examined using MTT, colony formation, transwell, wound healing, and EdU assays Results: TICRR expression was observed to be significantly elevated in LUAD tissues and cell lines, and its higher levels correlated with unfavorable patient outcomes and enrichment of malignant pathways, including EMT, E2F targets, and PI3K/AKT/mTOR signaling. High TICRR expression correlated with distinct somatic mutation patterns, increased tumor mutation burden, and elevated immune checkpoint expression. Conclusion: TICRR functions as a critical oncogenic driver in LUAD, promoting proliferation, invasion, and immune evasion. Targeting TICRR may represent a novel strategy for personalized treatment of LUAD.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.